Litcius/Paper detail

5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib

Yodita Asfaha, Lukas M. Bollmann, Alexander Jan Skerhut, Fabian Fischer, Nadine Horstick, Dennis Roth, Maria Wecker, Christian E. Mammen, Sander H. J. Smits, Georg Fluegen, Matthias U. Kassack, Thomas Kurz, Thomas Kurz

2023European Journal of Medicinal Chemistry18 citationsDOIOpen Access PDF

Topics & Concepts

ChemistryBortezomibIn vivoCytotoxicityPharmacologyCytotoxic T cellIC50Cancer researchIn vitroBiochemistryMultiple myelomaBiologyImmunologyBiotechnologyHistone Deacetylase Inhibitors ResearchPeptidase Inhibition and AnalysisProtein Degradation and Inhibitors
5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib | Litcius